UA87306C2 - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
UA87306C2
UA87306C2 UAA200612254A UAA200612254A UA87306C2 UA 87306 C2 UA87306 C2 UA 87306C2 UA A200612254 A UAA200612254 A UA A200612254A UA A200612254 A UAA200612254 A UA A200612254A UA 87306 C2 UA87306 C2 UA 87306C2
Authority
UA
Ukraine
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
inhibitors
compounds
Prior art date
Application number
UAA200612254A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристофер КАЛЛУС
Хольгер Хайч
Андреас Линденшмидт
Свен Грюнеберг
Хауке Силлат
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87306(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Publication of UA87306C2 publication Critical patent/UA87306C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение касается соединений формулы (Іа)ингибиторов активированного ингибитора, которые активируется тромбином фибринолиза.Соединения формулы (І) пригодны для получения лекарственных средств с целью профилактики и лечения заболеваний, которые протекают с тромбозами, эмболиями, гиперкоагуляцией или фибротическими изменениями.
UAA200612254A 2004-04-22 2005-07-04 Imidazole derivatives used as tafia inhibitors UA87306C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
UA87306C2 true UA87306C2 (en) 2009-07-10

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612254A UA87306C2 (en) 2004-04-22 2005-07-04 Imidazole derivatives used as tafia inhibitors

Country Status (35)

Country Link
EP (2) EP1864979B1 (ru)
JP (1) JP4939401B2 (ru)
KR (1) KR101162047B1 (ru)
CN (1) CN100572376C (ru)
AR (1) AR053302A1 (ru)
AT (2) ATE523505T1 (ru)
AU (1) AU2005238144B2 (ru)
BR (1) BRPI0510159A (ru)
CA (1) CA2563401C (ru)
CR (1) CR8650A (ru)
CY (1) CY1108087T1 (ru)
DE (2) DE102004020186A1 (ru)
DK (1) DK1740569T3 (ru)
EC (1) ECSP066941A (ru)
ES (1) ES2299026T3 (ru)
HK (1) HK1101823A1 (ru)
HR (1) HRP20080099T3 (ru)
IL (1) IL178672A (ru)
MA (1) MA28543B1 (ru)
MY (1) MY140903A (ru)
NI (1) NI200600217A (ru)
NO (1) NO20065320L (ru)
NZ (1) NZ550757A (ru)
PE (1) PE20060172A1 (ru)
PL (1) PL1740569T3 (ru)
PT (1) PT1740569E (ru)
RS (1) RS50553B (ru)
RU (1) RU2375356C2 (ru)
SI (1) SI1740569T1 (ru)
TN (1) TNSN06341A1 (ru)
TW (1) TWI359016B (ru)
UA (1) UA87306C2 (ru)
UY (1) UY28868A1 (ru)
WO (1) WO2005105781A1 (ru)
ZA (1) ZA200607668B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090087044A (ko) 2006-12-06 2009-08-14 사노피-아벤티스 ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US8470863B2 (en) * 2007-02-13 2013-06-25 Merck Sharp & Dohme, Corp. Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists
US8183381B2 (en) * 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
CN102056922B (zh) 2008-06-06 2013-11-20 赛诺菲-安万特 作为tafia抑制剂的大环脲和磺酰胺衍生物
US20110213143A1 (en) 2008-10-29 2011-09-01 Taisho Pharmaceutical Co., Ltd. Compound having tafia inhibitory activity
MY157304A (en) * 2009-05-15 2016-05-31 Sanofi Sa Process for the preparation of a compound useful as an inhibator of tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
DK2548871T3 (da) * 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
ES2608779T3 (es) 2010-03-18 2017-04-17 Daiichi Sankyo Company, Limited Derivado de ácido ciclopropanocarboxílico
WO2012062730A1 (en) * 2010-11-11 2012-05-18 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9156815B2 (en) 2011-11-25 2015-10-13 Sanofi Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
EP2782576B1 (en) 2011-11-25 2016-05-18 Sanofi Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
WO2014198620A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
CA2472239A1 (en) 2002-01-22 2003-07-31 Pfizer Inc. 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
ATE523505T1 (de) 2011-09-15
MY140903A (en) 2010-01-29
AR053302A1 (es) 2007-05-02
AU2005238144B2 (en) 2010-08-26
EP1740569B1 (de) 2008-02-20
ES2299026T3 (es) 2008-05-16
JP2007533672A (ja) 2007-11-22
ATE386737T1 (de) 2008-03-15
DE102004020186A1 (de) 2005-11-17
KR101162047B1 (ko) 2012-07-04
CN1950357A (zh) 2007-04-18
PT1740569E (pt) 2008-03-31
IL178672A0 (en) 2007-02-11
TWI359016B (en) 2012-03-01
WO2005105781A1 (de) 2005-11-10
NZ550757A (en) 2010-06-25
DE502005002927D1 (de) 2008-04-03
RU2375356C2 (ru) 2009-12-10
BRPI0510159A (pt) 2007-10-02
CN100572376C (zh) 2009-12-23
UY28868A1 (es) 2005-11-30
EP1864979B1 (de) 2011-09-07
HRP20080099T3 (en) 2008-03-31
CA2563401A1 (en) 2005-11-10
CR8650A (es) 2007-12-04
CA2563401C (en) 2012-08-07
HK1101823A1 (en) 2007-10-26
KR20070007346A (ko) 2007-01-15
RU2006141246A (ru) 2008-06-10
ECSP066941A (es) 2006-12-20
EP1740569A1 (de) 2007-01-10
CY1108087T1 (el) 2014-02-12
AU2005238144A1 (en) 2005-11-10
EP1864979A1 (de) 2007-12-12
IL178672A (en) 2011-08-31
NI200600217A (es) 2008-06-17
MA28543B1 (fr) 2007-04-03
JP4939401B2 (ja) 2012-05-23
TW200602325A (en) 2006-01-16
PL1740569T3 (pl) 2008-07-31
PE20060172A1 (es) 2006-03-31
ZA200607668B (en) 2008-03-26
DK1740569T3 (da) 2008-06-02
SI1740569T1 (sl) 2008-06-30
TNSN06341A1 (en) 2008-02-22
RS50553B (sr) 2010-05-07
NO20065320L (no) 2007-01-12

Similar Documents

Publication Publication Date Title
UA87306C2 (en) Imidazole derivatives used as tafia inhibitors
UA104137C2 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
WO2008033562A3 (en) Kinase inhibitor compounds
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
GEP20146125B (en) Aminopyrimidines as syk inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
EA201170872A1 (ru) Ингибиторы протеинкиназы
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010009736A (es) Compuesto heterociclico.
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
UA104002C2 (ru) МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa
MX2009005649A (es) Tratamiento para mieloma multiple.
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
MX2009005938A (es) 6-oxo-1,6-dihidro-pirimidin-2-ilos en el tratamiento de enfermedades proliferativas.
MX2009005516A (es) Derivados de urea y de sulfamida en calidad de inhibidores de tafia.
WO2010021934A3 (en) Azaindole inhibitors of iap